Haisco(SZ:002653) Xin Lang Cai Jing·2025-10-17 07:24Core Viewpoint - Haikang's stock price has shown a continuous upward trend, reflecting positive market sentiment and potential investment opportunities in the pharmaceutical sector [1][2]. Company Overview - Haikang Pharmaceutical Group Co., Ltd. was established on August 26, 2005, and went public on January 17, 2012. The company is located in Zedang Town, Shannan City, Tibet [1]. - The main business activities include research and development, manufacturing, and sales of chemical drugs [1]. - Revenue composition is as follows: anesthetic products 39.81%, cooperative product-related income 23.59%, other indications 17.02%, parenteral nutrition 10.32%, antiemetics for tumors 8.15%, and other supplementary income 0.86% [1]. Stock Performance - As of October 17, Haikang's stock price increased by 0.75% to 52.50 CNY per share, with a trading volume of 227 million CNY and a turnover rate of 0.89%. The total market capitalization is 58.796 billion CNY [1]. - The stock has risen for three consecutive days, with a cumulative increase of 6.49% during this period [1]. Fund Holdings - Southern Fund's Southern Medical Health Flexible Allocation Mixed A (000452) holds a significant position in Haikang, with 3.9138 million shares, unchanged from the previous period, accounting for 6.84% of the fund's net value [2]. - The fund has realized a floating profit of approximately 1.5264 million CNY today and 12.5241 million CNY during the three-day upward trend [2]. - The fund was established on January 23, 2014, with a current scale of 2.405 billion CNY and has achieved a year-to-date return of 45.86% [2].